Clinical trials are underway for patients with a variety of cancers who receive NKTR-214/bempegaldesleukin in combination with anti-PD-1 (nivolumab and pembrolizumab), anti-CTLA-4 (ipilimumab), and other agents. Here, CTLA4 is linked to cancer.